

# Index

---

- Aarhus Convention 9, 24–6, 33  
Agent Orange 77–8  
Agreement on Technical Barriers to Trade (TBT) 141–2  
Agreement on Trade Related Aspects of Intellectual Property Rights *see* TRIPS (Agreement on Trade Related Aspects of Intellectual Property Rights)
- Bacillus thuringiensis* (Bt.) 148–9  
Beck, Ulrich 75–83, 87  
bioethics *see* public bioethics  
*biosafety see safety*  
BSE (Bovine Spongiform Encephalopathy) crisis 12, 204
- Cartagena Protocol on Biosafety ‘available scientific evidence’ 131, 133  
*EC-Biotech* Panel 154  
LMOs 131–2  
precautionary principle in 132–5  
provisions of 129–33  
Codex Alimentarius Commission (Codex) 158–9  
and production of normative standards 160–62  
coexistence  
and ethical pluralism 184–5  
economic approach to 185  
limitations of 187–90  
measures in EU law 54–5  
rationales for 55–6  
segregation of GM crops 55, 177, 185–8  
Comitology 39, 109  
consumer autonomy *see* ethics:  
consumer concerns  
consumer choice *see* ethics: ethical  
plurality  
Contained Use Directive 43, 86, 226  
crop segregation *see* coexistence:  
segregation of GM crops
- Danish Council of Ethics, report of 215–8  
Dean, Mitchell 84–5  
Deliberate Release Directive (2001) 35–7  
and bifurcated risk regulation 63  
and environmental liability 57  
and precautionary principle 106–7  
authorization procedure 38–9  
for field trials of GM plants 44  
ethical consultation 178  
generation of data for  
decision-making 86  
opt-out clause 48  
power of EU Member States to take  
derogatory action 45  
scope of 38  
democratic deficit 18–20  
in EU regulation of deliberate release  
of GMOs 118  
in expert networks 163  
Diebold, Nicolas 170, 174  
Douglas, Mary 72–3, 75
- environmental guarantees 49–51,  
119–20, 122  
Environmental Liability Directive 57  
ethics  
consumer concerns 182–3  
ethical pluralism 182–5, 188–9  
expert advice 197  
in EGE report on EU GM agriculture  
212, 218

- supplementary ethics labelling 183–4
- European Commission
  - and coexistence measures 54–5, 184–8
  - and implementation of EU treaties 33
  - and liability measures 56–7
  - and precautionary principle 94, 107, 112–13
  - and public engagement 198–9
  - ethical consultation provisions 192
  - Life Sciences strategy 23–4, 199
  - ‘opt-out’ of GM agriculture for EU Member States 58–60
  - reliance on EFSA reports 113
  - White Paper on Food Safety 108–9
- European Food Safety Authority (EFSA)
  - and risk assessment 40, 70, 94, 108–13
  - as creator of scientific standards 108–10
  - legitimacy of ethical judgments of 183–4
- European Group on Ethics in Science and New Technologies (EGE)
  - advisory role 178
  - report on ethical scrutiny of GM agriculture 211–14
- fact-value divide 68–70
- Food and Feed Regulation (2003) 37–8
  - and labelling 52, 180–82
  - and liability 57
  - and risk 63, 86, 121
  - ethical consultation 178
  - safeguard clause 46–7, 121
  - supplementary ethics labelling 181–2
- food safety
  - and public opinion 12
  - and regulation of GMOs 38
  - and risk analysis 159
  - EGE on 212
  - EFSA *see* European Food Safety Authority (EFSA)
  - evaluation of 115
  - GAIEB on 206
- Food Safety Regulation 109, 113
- Foucault, Michel 83
- Fukuyama, Francis 1–2
- GAIEB (Group of Advisors on the Ethical Implications of Biotechnology) 192, 198
  - on food safety standards 206
  - role in European integration 223
- General Agreement on Tariffs and Trade (GATT), 1994
  - and non-discrimination *see* global rules: non-discrimination
  - general exceptions 138
  - protection of public morals *see* public morals
  - subordination of, to other agreements 139, 142
- genetically modified organisms (GMOs)
  - environmental risk assessment of 38, 48, 107, 110, 112
  - ethical scrutiny of research and development of 208–9
  - EU moratorium on 9–10, 34, 146
  - field trials of GM plants 44
  - public unease about 6–8, 14
  - side-effects of 87
- global rules
  - Advanced Informed Consent 130
  - Dispute Settlement Body of the WTO 137, 159, 162, 166
  - expert standards 167
  - jus cogens* 153
  - principle of non-discrimination 59, 142, 169
  - public morality *see* public morals
  - SPS Agreement *see* Sanitary and Phytosanitary (SPS) Agreement
  - TBT Agreement *see* Agreement on Technical Barriers to Trade (TBT)
  - WTO Agreement/GATT *see* World Trade Organization (WTO)
- GM Nation* 7
- Governmentality 83–5
- Habermas, Juergen 26–7

- harm  
 and precautionary principle 96, 98–9, 101  
 and risk 74, 176  
 environmental 208  
 problems with identification of 114  
 regulation of 80
- incertitudes *see* uncertainty  
*in-vitro* fertilization 191–2, 196  
 Irish Council for Bioethics 176, 201–4
- Knight, Frank 65  
 knowledge, instability of 66–8, 204–7  
 Kuhn, Thomas 20
- labelling  
 and ethical plurality 176–7, 179–81  
 and traceability 52–3  
 exclusion of certain foods from requirement of 53  
 ‘paper trail’ 52–3  
 supplementary ethics labelling 181–4  
 Labelling Regulation (2003) 34, 52–3  
 living modified organisms (LMOs) 130–33  
 Luhmann, Niklas 73–5, 89
- Mouffe, Chantal 126
- nanotechnology, and precaution 124–6  
 Nuffield Council on Bioethics 206
- O’Malley, Pat 85  
 ‘organized irresponsibility’ 79–81
- precautionary principle  
 and bifurcation of risk 107–8, 111  
 criticisms of 100–101  
*EC-Biotech* Panel on 153–4  
 in import of LMOs 131  
 in international legal frameworks 35, 109, 112, 122–4, 132–5  
 interpretations of 102–5  
 Rio Declaration formulation of 96  
 trigger for invocation of 99–102, 112–15, 123
- product safeguard measures 45–9, 119
- public bioethics  
 as a regulatory tool 193–4  
 committees *see* public bioethics committees  
 National Bioethics Organizations (NBOs) 194  
 role of experts in 195–7, 200
- public bioethics committees  
 creation of consensus in 199  
 ethical scrutiny of risk analysis by 207–8  
 ethical scrutiny of technological trajectories by *see* technological trajectories: public participation in ethical scrutiny of  
 expert dissent in 200  
 Irish Council *see* Irish Council for Bioethics  
 Warnock Committee 191
- public morality  
 general exception in GATT 138  
 myth of consensus 196  
 protection of in WTO regime 137–8, 168–74
- public participation  
 and impact assessments 212, 214, 219–22  
 and power imbalances 28  
 and public values 178, 182, 188–9  
 and risk 63–4, 71, 90, 118, 125  
 and technology regulation 4, 116  
 arguments for 23  
 EU policy commitment to 23–5, 32–4  
 global scope for 128–9, 137, 174  
 in EU regulation of GMOs 20, 22, 30, 61, 119, 157  
 in public bioethics 195, 224  
 trust and engagement 89, 126–8
- public sphere  
 and public bioethics 194–5, 198  
 nature of 26–8
- Red Book of the US National Research Council 82–3  
 Rights of farmers, to save seeds 213–4, 217–8

- risk
  - and danger 63, 89
  - and public engagement 88–90
  - as probability 65
  - as state of uncertainty 63
  - as tool for governance 84–6
  - bifurcation model of *see* fact-value divide
  - deficit model of public perception of 11–12
  - expert scientific advice on 21–2, 82–3
  - politicization of 72
- risk analysis by
  - procedural transparency of 86–7
- risk assessment
  - and EFSA 40, 70, 94, 108–13
  - and precautionary principle 98, 107, 113–14, 123
  - and public concerns 70, 206
  - and risk management 68–70, 107, 112–13, 166
  - and scientific evidence 144–5, 159
  - and technology impact assessment 219
  - competing values in 208
  - EC-Biotech* Panel on 147–53
  - environmental, of GMOs 38, 48, 107, 110, 112
  - EU courts' approach to 123
  - in authorization procedure for GMOs 38–40
  - in import of LMOs 131–2
  - in SPS Agreement 140–41
  - in TBT Agreement 142
  - limitations of 115
  - normativity of 68
  - public participation in 112–14, 125–6, 166, 168
  - techno-scientific approach to 64–5, 104–5, 123, 202
- risk management
  - and precautionary principle 98, 107, 111, 118
  - and risk assessment 68–70, 107, 112–13, 166
  - DSB on 166
  - political nature of 68, 70, 98, 107, 113
  - through committee procedure 113–14
  - through labelling 53
- risk regulation, EU
  - bifurcation of 63, 70
  - ethical scrutiny of *see* public bioethics committees: ethical scrutiny of
  - and precautionary principle 91–7
- Risk Society 76–83
- safety
  - and authorization of release of GMOs 38–44
  - and economic growth 118
  - and law 87–8
  - and post-release regulation of GMOs 45–50
  - and precaution 94, 98, 105, 115
  - and public trust and engagement 88–90, 124–7, 202
  - and public values 173
  - and risk 62–3, 67–8, 70, 73, 107
  - and WTO regime 128–9, 140
  - Cartagena Protocol *see* Cartagena Protocol on Biosafety
  - EGE on 218
  - erosion of scientific monopoly in ascriptions of 77–8
  - EU courts' decisions on 119–22
  - food *see* food safety
  - see also* risk; precautionary principle
  - Sanitary and Phytosanitary (SPS) Agreement 140–42
  - and Codex standards, DSB on 159
  - EC-Biotech* Panel decision 143, 145–53
  - 'insufficiency of scientific evidence' 141, 149–53, 159
  - interpretation of by WTO Panels 144–5
- science, post-normal 20–21, 114
- scientific evidence
  - and environmental guarantee measures 49, 51, 120
  - and law 164
  - and levels of protection 151–3, 168
  - and risk assessment 109, 166
  - and safeguard clauses 45, 149–50

- and scientific advice 113
- and scientific certainty 165
- available *see* Cartagena Protocol on Biosafety: 'available scientific evidence'
- definitions of 51, 120
- insufficiency of *see* Sanitary and Phytosanitary (SPS) Agreement: 'insufficiency of scientific evidence'
- side-effects, latent 77–9
- SPS Agreement *see* Sanitary and Phytosanitary (SPS) Agreement
- TBT Agreement *see* Agreement on Technical Barriers to Trade (TBT)
- technological trajectories 5, 15
  - and precautionary principle 98, 102–4, 114–16
  - and risk 82
  - path-dependency of 4
  - public participation in ethical scrutiny of 198–200, 208–10
- technology impact assessment
  - definition of 219
  - EGE report recommendations on 212–14
- traceability *see* labelling: and traceability
- TRIPS (Agreement on Trade Related Aspects of Intellectual Property Rights) 171
- uncertainty 66–7, 103, 111
  - and risk 63, 65–6, 73–4, 78, 84, 151, 164
  - see also* risk assessment; precautionary principle
- public participation in
  - characterization of 98–100, 114, 133
- regulatory responses to 94, 96, 98–9
- utilitarianism
  - dissent about utility 216–17
  - utility assessment 215–16, 219
- see also* harm
- World Trade Organization (WTO)
  - Appellate Body
    - Australia-Salmon* 147
    - China-Audiovisuals* 169, 172
    - EC-Hormones I* 107, 122, 148, 166, 168
    - EC-Hormones II* 151, 153, 168
    - Japan-Apples* 141
    - US-Gambling* 169, 172
    - US-Shrimp* 138–9, 154
  - EC-Biotech Panel
    - definition of risk assessment
    - general moratorium on GM products 146
    - 'insufficiency of scientific evidence' 149–50
    - on precautionary principle 153–4
    - research and review requirements 152
  - examination of general exceptions to GATT 138
  - SPS Agreement *see* Sanitary and Phytosanitary (SPS) Agreement
  - TBT Agreement *see* Agreement on Technical Barriers to Trade (TBT)
- Wynne, Brian 77–8, 99, 111, 204–6

